Marker for gastrointestinal tumors

Patent metadata

Field	Value
Publication number	US-11442065-B2
Application number	US-202016834981-A
Country	US
Kind code	B2
Filing date	Mar 30, 2020
Priority date	May 30, 2019
Publication date	Sep 13, 2022
Grant date	Sep 13, 2022

Abstract

The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.

First claim

The invention claimed is:

1. A method for selectively treating gastrointestinal cancer in a patient in need thereof, comprising the steps of:
(a) selecting a patient for treatment with an anticancer agent;
(b) providing a series of biological samples from the subject over a time period;
(c) analyzing the series of biological samples to determine the amount of OSTERIX marker in the subject's biological samples;
(d) determining the change in the amount of OSTERIX marker in the biological samples; and
(e) determining based upon the change whether to initiate or continue the prophylaxis or therapy of gastrointestinal cancer, and
(f) administering a therapeutically effective amount of an anticancer agent or method to the patient,
wherein the anticancer agent or method is selected from the group consisting of:
(i) non-drug treatments selected from the group consisting of Radio Frequency Ablation (RFA) and Hepatic Arterial Chemoembolization (HACE);
(ii) adjuvant or neoadjuvant therapy selected from the group consisting of imatinib, sunitinib, regorafenib, and avapritinib;
(iii) EGFR inhibitors selected from the group consisting of cetuximab, panitumumab, and necitumumab;
(iv) tyrosine kinase inhibitors selected from the group consisting of erlotinib, geftinib, afatinib, lapatinib, and osimertinib;
(v) cetuximab, either alone or combination with 5-FU, leucovorin, and irinotecan;
(vi) panitumumab;
(vii) regorafenib;
(viii) trifluridine/tipiracil; and
(ix) immune checkpoint inhibitors selected from the group consisting of nivolumab and ipilimumab.

2. The method of claim 1 , wherein the selecting a patient for treatment with an anticancer agent comprises identifying gastrointestinal stem cells in a gastrointestinal sample.

3. The method of claim 1 , wherein the selecting a patient for treatment with an anticancer agent comprises identifying gastrointestinal stem cells in a gastrointestinal sample and analyzing the gastrointestinal sample to determine the amount of OSTERIX marker.

4. The method of claim 1 , wherein the selecting a patient for treatment with an anticancer agent comprises identifying gastrointestinal stem cells in a gastrointestinal sample by the expression of the OSTERIX marker in the cells in the gastrointestinal sample.

5. The method of claim 1 , wherein the method for selectively treating gastrointestinal cancer in a patient further comprises the step of:
(g) determining whether to continue prophylaxis or treatment of gastrointestinal cancer in the subject.

Assignees

• Rhode Island Hospital

Inventors

• Yang Wentian
• Wang Lijun
• Moore Douglas C

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/5753 Primary

  of the stomach or small intestine · CPC title

• G01N33/56966

  Animal cells · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title